## UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SANDRA L. KINNEY, et al., No. C-12-4477 EMC

Plaintiffs,	RELATED TO
v.	No. C-12-4478 EMC No. C-12-4615 EMC
BRISTOL-MYERS SQUIBB COMPANY, et al.,	No. C-12-4616 EMC No. C-12-4617 EMC No. C-12-4619 EMC
Defendants.	No. C-12-4619 EMC No. C-12-4633 EMC No. C-12-4641 EMC
AND ALL RELATED ACTIONS.	No. C-12-4642 EMC No. C-12-4803 EMC
	ORDER STAYING LITIGATION

At a hearing held on November 30, 2012, the Court discussed with the parties whether there should be a stay in the above-referenced lawsuits in light of Bristol-Myers and Sanofi's motion to transfer and consolidate with the Judicial Panel on Multidistrict Litigation (which was filed on October 15, 2012). See Docket No. 19 (notice). Having considered the parties' positions, as articulated in their joint case management statement and at the hearing, the Court concludes that a stay is warranted. There is a reasonable likelihood that issues currently before this Court (e.g., fraudulent joinder, CAFA jurisdiction, and/or procedural misjoinder) will arise in other Plavix cases filed in other district courts. Moreover, Plaintiffs have not adequately established that they would be

prejudiced by any delay resulting from a stay, particularly where the stay is likely to be brief in

PENDING DECISION BY MDL

JUDICIAL PANEL

length. See Docket No. 24 (CMC St. at 4) (stating Defendants' best estimate that the panel hearing will take place on January 31, 2013).

Accordingly, the Court hereby **STAYS** the litigation in each of the above-referenced actions pending a decision by the MDL Judicial Panel on the motion to transfer and consolidate.

IT IS SO ORDERED.

Dated: December 3, 2012

United States District Judge